Transplantation and Cellular Therapy | 2021
Planned granulocyte colony-stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy.
Orfali N, Zhang M-J, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Diaz MA, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, van Besien K, Eapen M
PubMed
PMID: 34507002
Abstract
Related Articles
CIBMTR Study #: GS19-03a